ARTICLE | Company News
Eli Lilly, bioMerieux to develop ACAT inhibitor
May 3, 2001 7:00 AM UTC
LLY and bioMerieux- Pierre Fabre (Paris, France) will develop bioMerieux's eflucimibe acyl-CoA:cholesterol acyltransferase inhibitor to treat atherosclerosis. The compound is in Phase I testing. The c...